Optimizing Genotype Matched Clinical Trial (GMCT) accrual in a community oncology program (COP).

e18036Background: While molecular profiling (MP) is becoming widely accessible, clinician understanding may be a barrier to GMCT enrollment. MP programs at academic medical centers report GMCT enrollment rates at 5-17% of eligible patients. To advance precision medicine, this process must be adapted to serve COPs. Methods: We performed a prospective MP study (NCT02416518) at Sanford Health, a predominantly rural health care system with 4 participating COP sites. The primary outcome of the study was feasibility of testing in this setting. Secondary outcomes included correlating GMCT enrollment, impact on treatment decisions, and patient outcomes. Eligible patients included those with incurable solid tumor malignancies that had progressed on ≥ 1 prior line of therapy or had no standard first-line treatment options available, an ECOG PS of ≤ 1, adequate organ function, and recent tissue biopsy ( ≤ 14 weeks) available for MP. MP was performed using FoundationOne. A weekly, video conferenced genomic tumor boar...